Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | CA9 | Q16790 | 1/20 | 0.39 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7286496 | 1.00 | TDP1 (0.50) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9262163 | 1.00 | TDP1 (0.50) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9574258 | 1.00 | TDP1 (0.50) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9260474 | 0.98 | TDP1 (0.52) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL6942905 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL454150 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9262777 | 0.92 | IDO1 (0.52) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL7621746 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9257077 | 0.92 | TDP1 (0.53) | TDP1L3MBTL1MEN1KMT2AHRH3 | |
| SCHEMBL9257411 | 0.92 | IDO1 (0.52) | TDP1L3MBTL1MEN1KMT2AHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2010-08-19 | — | — | US | disclosed |
| US-7709511-B2 | Benzothiazolone derivatives | ASTRAZENECA AB (SE) | 2010-05-04 | — | — | US | disclosed |
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | ASTRAZENECA AB (SE) | 2008-12-04 | — | — | US | disclosed |
| EP-1915354-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | AstraZeneca AB (SE) | 2008-04-30 | — | — | EP | disclosed |
| WO-2007018461-A1 | NOVEL BENZOTHIAZOLONE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-02-15 | — | — | WO | disclosed |
| WO-1995019336-A1 | PHENYL ETHANOL AMINE ETHERS AND USES THEREOF AS β-ADRENO-RECEPTOR AGONISTS | IOVIS BIOMEDICAL AND PHARMACEUTICAL CONSULTANTS (NL) | 1995-07-20 | — | — | WO | disclosed |
| US-5243076-A | Adrenergic stimulant intermediates | GLAXO GROUP LTD. | 1993-09-07 | — | — | US | disclosed |
| US-5225445-A | Respiratory system disorders | GLAXO GROUP LTD. | 1993-07-06 | — | — | US | disclosed |
| US-5126375-A | Asthma, chronic bronchitis | GLAXO GROUP LTD. (GB) | 1992-06-30 | — | — | US | disclosed |
| US-5091422-A | Treating inflammatory or allergic skin disease, lowering gastric acidity | GLAXO GROUP LIMITED (GB) | 1992-02-25 | — | — | US | disclosed |
| US-5006556-A | Dichloroaniline derivatives for the therapy or prophylaxysis of a disease associated with reversible airway obstruction | GLAXO GROUP LIMITED (GB) | 1991-04-09 | — | — | US | disclosed |
| US-4992474-A | Adrenergic stimulants | GLAXO GROUP LTD. (GB) | 1991-02-12 | — | — | US | disclosed |
| US-4943591-A | TREATMENT OF ASTHMA AND BRONCHITIS | GLAXO GROUP LIMITED (GB) | 1990-07-24 | — | — | US | disclosed |
| EP-0181709-B1 | DICHLOROANILINE DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1990-05-09 | — | — | EP | disclosed |
| EP-0181709-A1 | Dichloroaniline Derivatives | GLAXO GROUP LIMITED (GB) | 1986-05-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080300275-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | TDP1 2812/4885L3MBTL1 1114/4885MEN1 3338/4885 |
| US-20100210688-A1 | Novel Benzothiazolone Derivatives | NR0B1, RB1, CCND1 | TDP1 2812/4885L3MBTL1 1114/4885MEN1 3338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.